DarioHealth Stock Forecast, Price & News

+0.23 (+1.24 %)
(As of 04/23/2021 01:07 PM ET)
Today's Range
Now: $18.73
50-Day Range
MA: $19.97
52-Week Range
Now: $18.73
Volume1,867 shs
Average Volume279,911 shs
Market Capitalization$288.42 million
P/E RatioN/A
Dividend YieldN/A
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
DarioHealth logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:DRIO
Year FoundedN/A



Sales & Book Value

Annual Sales$7.56 million
Book Value$8.45 per share


Net Income$-17,740,000.00
Net Margins-337.55%


Market Cap$288.42 million
Next Earnings Date5/11/2021 (Estimated)
OptionableNot Optionable


DarioHealth (NASDAQ:DRIO) Coverage Initiated at Stifel Nicolaus
March 29, 2021 |
A Preview Of DarioHealth's Earnings - Yahoo Finance
March 8, 2021 |
A Preview Of DarioHealth's Earnings
March 8, 2021 |
See More Headlines


Overall MarketRank

1.53 out of 5 stars

Medical Sector

480th out of 2,024 stocks

Surgical & Medical Instruments Industry

39th out of 169 stocks

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.23 (+1.24 %)
(As of 04/23/2021 01:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRIO News and Ratings via Email

Sign-up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DarioHealth (NASDAQ:DRIO) Frequently Asked Questions

Is DarioHealth a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DarioHealth stock.
View analyst ratings for DarioHealth
or view top-rated stocks.

What stocks does MarketBeat like better than DarioHealth?

Wall Street analysts have given DarioHealth a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DarioHealth wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting DarioHealth?

DarioHealth saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 280,000 shares, an increase of 58.8% from the February 28th total of 176,300 shares. Based on an average trading volume of 274,400 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.4% of the company's shares are short sold.
View DarioHealth's Short Interest

When is DarioHealth's next earnings date?

DarioHealth is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for DarioHealth

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) released its quarterly earnings data on Monday, March, 8th. The company reported ($1.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.44. The company earned $2.08 million during the quarter, compared to analyst estimates of $2.12 million. DarioHealth had a negative net margin of 337.55% and a negative trailing twelve-month return on equity of 120.46%.
View DarioHealth's earnings history

How has DarioHealth's stock price been impacted by COVID-19 (Coronavirus)?

DarioHealth's stock was trading at $6.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRIO stock has increased by 167.8% and is now trading at $18.45.
View which stocks have been most impacted by COVID-19

What guidance has DarioHealth issued on next quarter's earnings?

DarioHealth updated its FY 2020 Pre-Market earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.6-7.6 million, compared to the consensus revenue estimate of $7.63 million.

What price target have analysts set for DRIO?

7 brokerages have issued twelve-month price objectives for DarioHealth's shares. Their forecasts range from $10.00 to $35.00. On average, they anticipate DarioHealth's share price to reach $25.75 in the next twelve months. This suggests a possible upside of 39.6% from the stock's current price.
View analysts' price targets for DarioHealth
or view top-rated stocks among Wall Street analysts.

Who are DarioHealth's key executives?

DarioHealth's management team includes the following people:
  • Mr. Erez Raphael, CEO & Director (Age 48, Pay $721.38k)
  • Mr. Zvi Ben David, CFO, Treasurer & Sec. (Age 60, Pay $175.3k)
  • Mr. Dror Bacher, Chief Operating Officer (Age 46, Pay $249.44k)
  • Mr. Olivier R. Jarry, Sr. VP of Strategy & Bus. Devel. (Age 60, Pay $160.94k)
  • Mr. Richard A. Anderson, Pres & GM of North America (Age 52)
  • Dov Oppenheim, Co-Founder & Production Chief
  • Claudia Levi, Content & Communications Mang.
  • Ms. Suzanne Bedell, VP of Marketing
  • Mr. Jean Christophe Muyl, Head of Commercialization North America
  • Yinon Amir, Head of Software Innovation

Who are some of DarioHealth's key competitors?

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.10%). Company insiders that own DarioHealth stock include Adam K Stern, Erez Raphael and Yoav Shaked.
View institutional ownership trends for DarioHealth

Which institutional investors are buying DarioHealth stock?

DRIO stock was purchased by a variety of institutional investors in the last quarter, including Calamos Advisors LLC. Company insiders that have bought DarioHealth stock in the last two years include Adam K Stern, Erez Raphael, and Yoav Shaked.
View insider buying and selling activity for DarioHealth
or or view top insider-buying stocks.

How do I buy shares of DarioHealth?

Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $18.45.

How much money does DarioHealth make?

DarioHealth has a market capitalization of $284.11 million and generates $7.56 million in revenue each year. The company earns $-17,740,000.00 in net income (profit) each year or ($8.00) on an earnings per share basis.

How many employees does DarioHealth have?

DarioHealth employs 127 workers across the globe.

What is DarioHealth's official website?

The official website for DarioHealth is

Where are DarioHealth's headquarters?

DarioHealth is headquartered at 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900.

How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected]

This page was last updated on 4/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.